Skip to main content

Gail India (Rs. 348.00) (Code : 532155)

Gail India (Rs. 348.00) (Code : 532155) : The GAIL India stock gained 10 per cent in three trading sessions last week on some positive news. The company stands to be a key beneficiary of the draft hydrocarbon policy announced earlier last week. If implemented, this will free pricing of domestic gas (currently regulated), which would boost gas production. This means utilisation of GAIL and other gas pipeline companies could improve significantly over the next few years. GAIL has been operating its pipelines below 40 per cent utilisation for the past few quarters. Second, Mumbai’s sole authorised distributor of CNG and PNG - Mahanagar Gas- has filed its draft prospectus on November 16, in which GAIL is looking to sell about 14 per cent stake (of its nearly 50 per cent shareholding). This monetisation will rub off favourably on GAIL and improve its cash kitty. Mahanagar Gas is India’s third largest city gas distribution company and a higher than estimated initial public offering (IPO) valuation would give a leg-up to GAIL’s sum of the parts valuations.Two leading brokerages BNP Paribas and Goldman Sachs, recently upgraded the stock.The stock is risk free at this level and has huge opporutnity. Buy.

Comments

  1. Ratul27 November 2015 at 23:51

    This comment has been removed by the author.

    ReplyDelete
  2. Ratul27 November 2015 at 23:52

    This comment has been removed by the author.

    ReplyDelete

Post a Comment

Popular posts from this blog

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News*   *TCI FINANCE LTD (501242 & NSE) (31)*   Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc.   The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL   The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services.   *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...
1 comment
Read more

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...
1 comment
Read more

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals  reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...
Post a Comment
Read more